• Skip to primary navigation
  • Skip to content
  • Skip to footer

Biolocity

Emory and Georgia Tech

  • Home
  • Funding
    • Application
  • Lab2Launch
  • Approach
    • Program History
  • Team
    • Oversight Committee
  • Success Stories
    • Funded Projects
    • Testimonials
  • Recent News
  • DRIVe
  • Legal Office Hours
  • B2MTalks
  • Events
    • Resources
You are here: Home / Recent News

Recent News

November 17, 2022 by aheard6

Lab2Launch Now Accepting Applications!

As part of Emory School of Medicine’s commitment to advance bio innovation and entrepreneurship, Lab2Launch is designed to provide capital-efficient access to flexible coworking and wet laboratory space to Emory-affiliated companies developing promising technologies that ultimately improve patient health.

If you are a founder looking for wet lab space, please apply at https://bit.ly/lab2launchapp.

If you have any questions about the application process and Lab2Launch, visit our website.  in general, feel free to reach out to

For a quick reference of our offerings, please view/download our brochure.

Filed Under: Commercialization, News

August 4, 2022 by aheard6

Biolocity Awards 6 Innovative Technologies with Commercialization Support

  • Thomas Wingo, MD, Alex Kotlar, PhD, Dave Cutler, PhD: Bystro
  • DexaPatch Team
    Andrés Garcia, PhD, Adam Klein, MD, Stephen Linderman, PhD, MD, Daniel Refai, MD: DexaPatch
  • MagTrack
    Nordine Sebhki, PhD, Omer Inan, PhD, Arpan Bhavsar, MS: MagTrack
  • CXCR4 Team
    Dennis Liotta, PhD, John Petros, MD, Haydn Kissick, PhD, Eric Miller, PhD: CXCR4
  • Susan Thomas, PhD: ProLymph Nano

The Biolocity program has selected six promising technologies with the ability to impact patient health for its 2022-2023 cohort of Biolocity Launch. This year-long collaboration helps awardees commercialize their innovations by advancing through critical milestones.

The program includes mentoring from business advisors, project management support, and funding to accelerate technology development and reach commercial milestones. Housed in the Wallace H. Coulter Department of Biomedical Engineering, Biolocity funding is open to all faculty at Emory University and Georgia Tech.

“There is a rich pipeline of promising patient-impacting technologies being developed at Emory University and Georgia Tech,” says Courtney Law, Ph.D., managing director of Biolocity. “This year’s applicant pool was very competitive, and the projects selected to be a part of this cohort have a strong potential for commercialization. We are excited to work with these passionate innovators to advance their technologies toward the market and ultimately patient impact.”

Biolocity selects projects through an annual, multi-stage application process that allows university innovators to receive pitch coaching, market assessments, and competitive analysis to cultivate commercial success. Faculty members work with entrepreneur advisors to de-risk their technology through each application stage. The final cohort is determined by an oversight committee of venture capitalists, entrepreneurs, clinicians, biomedical engineers, and university technology transfer experts.

This year’s cohort includes:

  • Athena: Athena is an early-stage cell therapy company developing a mesothelin-specific chimeric antigen receptor (CAR) T cell product, for the treatment of mesothelioma and other mesothelin expressing solid tumors. Principal Investigator: Crystal Paulos, Ph.D. (Emory University).
  • Bystro by revXon: A search engine for your life-sciences data. Principal Investigator: Thomas Wingo, MD (Emory University).
  • DexaPatch: Low-swelling, steroid-releasing, implantable hydrogel platform to reduce post-operative inflammation in tight surgical spaces. Principal Investigators: Andrés Garcia, Ph.D. (Georgia Tech), Adam Klein, M.D., Daniel Refai, M.D., Stephen Linderman, M.D., Ph.D. (Emory).
  • MagTrack: MagTrack is a wearable alternative controller that simplifies power wheelchair driving and the control of digital devices for people living with tetraplegia. Principal Investigators: Nordine Sebhki, Ph.D., and. Omer Inan, Ph.D. (Georgia Tech).
  • Orally Bioavailable CXCR4 Antagonists for the Treatment of Cancer: Best-In-Class Orally Bioavailable CXCR4 Antagonists Heat Up Solid Tumors. Principal Investigators: Dennis Liotta, Ph.D., Eric Miller, Ph.D., Haydn Kissick, Ph.D., and John Petros, M.D. (Emory University).
  • ProLymph Nano: Drug delivery technology unlocks new market opportunities by targeting the lymphatic system. Principal Investigator: Susan Thomas, Ph.D. (Georgia Tech).

In addition to project management and mentorship, awardees gain access to resources including incubators, accelerators, and venture capitalists that can potentially translate into follow-on investment or other business opportunities upon graduation from the Biolocity program.

Learn more about Biolocity and our portfolio at biolocity.org.

Filed Under: Funding, News

September 8, 2021 by Christina Wessels

Biolocity Selects 5 Promising Technologies for Funding

  • SANICKA TEAM
    Nicki Panoskaltsis, MD, PhD, Sakis Mantalaris, PhD, and Ana Quiroga, PhD: Sanicka
  • Hong Yeo
    Hong Yeo, PhD: Sleep Monitoring BioPatch
  • NiPro
    Nick Boulis, MD: NiPro
  • Agrithera Team
    Dennis Liotta, PhD, Scott Myers, PhD, Stephen Traynelis, PhD, and Luke Hodson, PhD: Agrithera
  • Ureatics Team
    Xiaonan Wang, PhD, Jeff Sands, PhD, Janet Klein, PhD: Urearetics

The Biolocity program has selected five promising and patient-focused technologies for its new cohort of Biolocity Launch, a year-long collaboration that helps faculty members commercialize their innovations.

The program includes mentoring from business advisors, project management support, and funding to accelerate technology development and reach commercial milestones. Housed in the Wallace H. Coulter Department of Biomedical Engineering, Biolocity is open to all faculty at Emory University and Georgia Tech.

“We are fortunate that, despite the pandemic, there is a rich pipeline of promising patient-impacting technologies being developed at Emory University and Georgia Tech,” said Courtney Law, managing director of Biolocity. “This year’s applicant pool was competitive, and the projects selected to be a part of this cohort have a strong potential for commercialization. These innovators are passionate about improving human health, and we are excited to work with them to advance their technologies toward the market.”

Biolocity selects projects through an annual, multi-stage application process that provides university innovators with the opportunity to receive pitch coaching, market assessments, and competitive analysis to cultivate commercial success. Faculty members work with entrepreneur advisors to de-risk their technology through each application stage with the final cohort determined by an oversight committee of venture capitalists, entrepreneurs, clinicians, biomedical engineers, and university technology transfer experts.

Since 2015, the program has awarded more than $8.7 million across 58 projects, generating over 10 times that much follow-on investment.

This year’s cohort includes:

  • Agrithera: A therapeutic strategy to overcome the pharmacological drawbacks of cannabidiol (CBD) for epilepsy treatment by creating precursor molecules that metabolize to CBD in the body. Principal Investigators: Dennis Liotta, Ph.D., and Stephen Traynelis, Ph.D. (Emory University).
  • NiPro: A customized nipple prosthesis with a subcutaneous anchoring system to help patients with body image issues after breast reconstruction. Principal Investigator: Nick Boulis, M.D. (Emory University).
  • Sanicka: A clinical decision support tool to aid treatment selection and optimization for leukemia patients. Principal Investigators: Ana Quiroga, Ph.D., and Sakis Mantalaris, Ph.D., (Georgia Tech); Nicki Panoskaltsis, M.D., Ph.D. (Emory University).
  • Sleep Monitoring Biopatch: A soft, wearable biosensor patch and accompanying software to enable at-home sleep testing. Principal Investigators: Hong Yeo, Ph.D. (Georgia Tech) and Paul Zolty, M.D. (Piedmont Hospital).
  • Urearetics: A novel mechanism to treat uremic pericarditis and pericardial effusions in chronic kidney disease patients by inhibiting urea transport. Principal Investigators: Jeff Sands, M.D.; Janet Klein, Ph.D.; and Xiaonan Wang, M.D. (Emory University).

This is the first year that project funding for Biolocity has been expanded through a gift to the Emory School of Medicine from John and Rosemary Brown. They established an innovation-to-market fund to take a multi-pronged approach to advancing new technologies, including support for Biolocity.

“We are grateful for the generosity of the Brown Innovation Fund, which has allowed us to expand our commercialization support of technologies at Georgia Tech and Emory University. The Brown family’s vision to build partnerships across campuses allows us to continue our goal to support human health innovation at both institutions,” Law said.

Learn more about Biolocity and our portfolio at biolocity.org.

 

Filed Under: Funding, News

May 15, 2021 by Christina Wessels

$1.6M Raise for NephroDI Therapeutics

Biolocity graduate company, NephroDI Therapeutics, recently raised $1.6M to advance the development of a treatment for Nephrogenic Diabetes Insipidus (NDI), a pediatric kidney disease.  The team is collaborating with Xontogeny, a Boston based life sciences accelerator, to support their creation of therapies to treat children suffering from NDI.  Learn more about their collaboration here.

The NephroDI Team, Dr. Jeff Sands and Dr. Janet Klein, received support from the Biolocity program in 2018 and we are thrilled for their continued success and technology development.

“The Biolocity team provided invaluable assistance that moved our project from an NIH focus to a commercial venture. They recognized the value of our technology and how to promote it to industry. We would not have succeeded without their expertise.”

– Jeff M. Sands, MD, Renal Division Director, Emory University

Filed Under: News, Technology

April 28, 2021 by Christina Wessels

$11M Awarded for Study of Heteroresistance

Congratulations to David Weiss, PhD, co-PI of the Heteroresistance AST team, currently participating in the Biolocity Launch program. David Weiss, is the director of Emory’s Antibiotic Resistance Center and his team received a five-year $11 million grant from NIAID to continue their work in studying heteroresistance to treat bacterial infections.

Read More Here

Filed Under: Commercialization, News

April 15, 2021 by Christina Wessels

Sanguina Announces Collaboration with AstraZeneca

Congratulations to Biolocity graduate company, Sanquina, on their newly announced collaboration with AstraZeneca on a study to develop a custom version of AnemoCheck Mobile, a smartphone application that provides noninvasive and equipment-free hemoglobin levels for patients with anemia of chronic kidney disease. Learn more about the collaboration here.

The AnemoCheck/Sanguina Team, Dr. Wilbur Lam and Erika Tyburski, received support from the Biolocity program (then the Coulter Translational Program) in 2016.  We are excited for their continued success and this new collaboration with AstraZeneca!

“Biolocity enabled us to receive an FDA 510(k) clearance on our first generation product. We couldn’t have done it without the support of Biolocity.”

– Erika Tyburski, AnemoCheck

Filed Under: Commercialization, News

  • Page 1
  • Page 2
  • Page 3
  • …
  • Page 6
  • Next Page »

Footer

Connect with us

  • Email
  • Facebook
  • LinkedIn
  • Twitter

Keep In Touch

Register here to receive our emails on upcoming events and funding opportunities.

Copyright © 2023 · Executive Pro on Genesis Framework · WordPress · Log in